PRTN3 and rheumatoid arthritis: The UK trial, Abatacept Study to Determine the Effectiveness in Preventing the Development of Rheumatoid Arthritis in Patients with Undifferentiated inflammatory Arthritis (ADJUST) study enrolled ACPA positive, individuals with UA to receive 8 intravenous (IV) injections of abatacept or placebo for 6 months with two years of follow up (165).